OncoMatch/Clinical Trials/NCT06266832
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
Is NCT06266832 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Oxaliplatin for rectal adenocarcinoma.
Treatment: Adebrelimab · Oxaliplatin · Capecitabine — To evaluate the efficacy, safety and organ retention rate of short-course radiation combined with Adebrelimab and CAPEOX neoadjuvant therapy in patients with MSS/pMMR ultra low rectal adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Colorectal Cancer
Biomarker criteria
Required: Mismatch-repair proficient (pMMR / MSS)
MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment
Disease stage
Required: Stage I, II, III
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
White blood cell count >3.5×10^9/L, absolute value of neutrophils >1.8×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥100g/L
Kidney function
24h creatinine clearance >50mL/min or serum creatinine <1.5 times the upper limit of normal
Liver function
Total bilirubin ≤ 1.25 times the upper limit of normal; ALT and AST < 5 times the upper limit of normal
Laboratory inspections must meet the following standards: White blood cell count >3.5×10^9/L, absolute value of neutrophils >1.8×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥100g/L; INR≤1.5, and APTT≤1.5 times the upper limit of normal or partial prothrombin time (PT) ≤1.5 times the upper limit of normal; Total bilirubin ≤ 1.25 times the upper limit of normal; ALT and AST < 5 times the upper limit of normal; 24h creatinine clearance >50mL/min or serum creatinine <1.5 times the upper limit of normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06266832 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MSH2?
Yes, MSH2 proficient MMR is a required biomarker for enrollment.
Does this trial require MSH6?
Yes, MSH6 proficient MMR is a required biomarker for enrollment.
Does this trial require MLH1?
Yes, MLH1 proficient MMR is a required biomarker for enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages